Replies to post #20754 on Marker Therapeutics Inc (MRKR)

[Stockdoggy]

This is my main hesitation in adding more shares. I own a pretty good chunk, but the whole immunotherapy space is crowded and evolving very quickly. TPIV appears a bit late to the party, but not a real big deal if results turn out to be better than predecessors. If I am wrong, somebody correct me...